查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869953

癌症切片检查市场规模、份额和趋势分析报告：按产品、类型、应用、地区和细分市场预测（2025-2033 年）

Cancer Biopsy Market Size, Share & Trends Analysis Report By Product (Instruments, Kits And Consumables, Services), By Type (Tissue Biopsies, Liquid), By Application, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

癌症切片检查市场摘要

2024年全球癌症切片检查市场规模估计为323.2亿美元，预计2033年将达到656.8亿美元。

预计从 2025 年到 2033 年，该市场将以 8.3% 的复合年增长率成长。这一市场成长是由癌症发病率的上升所驱动的，这促使人们需要创新的诊断技术，以便为患者提供早期有效的诊断解决方案。

此外，人们对遗传性肿瘤疾病的认识不断提高，以及基因检测的日益普及，预计将进一步推动癌症切片检查行业的成长。根据美国美国癌症研究所 (NCI) 2022 年的最新数据，光是在美国就将新增约 2,000 万例癌症病例，全球整体将有约 970 万人死于癌症。这些庞大的数字凸显了癌症负担的日益加重，同时也为市场带来了巨大的成长机会。

由于液态生物检体技术的优势，大规模平行基因组学（NGS）已成为一项快速发展且日新月异的技术，其应用范围不断扩大，涵盖多种人类产品类型。分子突变的日益多样化推动了NGS的普及，因为它为临床癌症检测提供了一种经济高效的方法。对肿瘤异质性（同时评估多个基因）和基因谱分析的需求不断增长，也推动了液态生物检体的广泛应用，预计这将进一步促进市场成长。此外，液态生物检体已成为多种癌症诊断和筛检的重要工具，包括摄护腺癌、乳癌、非小细胞肺癌、大肠癌和卵巢癌。

疾病发生率的上升推动了对早期癌症诊断的需求。例如，根据美国癌症协会发布的《2024年全球癌症统计》，2022年全球将新增约2,000万例癌症病例，导致970万人死于癌症。此外，预计到2050年，癌症病例数将达到3,500万例。如果在癌症发生转移之前，能够早期发现并将其控制在原发器官内，则生存率将显着提高，治癒的几率也会增加。早期发现，特别是透过高效的筛检项目，对于降低癌症死亡率至关重要。与延迟发现相比，早期发现可使患者的存活率提高5到10倍。转移后发现的癌症，其5年癌症特异性存活率仅为21%，而早期发现且仍处于局部阶段的癌症，其5年癌症特异性存活率则高达89%。

此外，各组织不断加强宣传活动是推动全球诊断产品需求的主要因素。美国疾病管制与预防中心（CDC）、美国（WHO）、美国国家子宫颈癌联盟和美国预防服务工作小组等机构推动的合作与协作，预计将透过提高子宫颈癌筛检率来促进市场成长。此外，主要市场参与者正积极采取措施提高大众对子宫颈癌、外阴癌和阴道癌的认识，这有望鼓励人们定期进行筛检。

例如，2024年，印度、美国、澳洲和日本推出了「四方抗癌登月倡议」 ，重点在于消除印度-太平洋地区的子宫颈癌。同样，2024年10月，雪梨新南威尔斯大学（UNSW）收到太古集团2590万美元的捐款，使该校的柯比研究所能够在七个太平洋岛国（斐济、吉里巴斯、马绍尔群岛共和国、萨摩亚、所罗门群岛、东加和瓦努阿图）为13万名女性进行子宫颈癌筛检。

此外，人们对早期诊断、可用治疗方案以及治疗方法的进步认识不断提高，显着改善了患者的治疗效果。根据美国癌症研究协会发布的《癌症进展报告》，2024年美国预计将新增约2,001,140例癌症病例，约有611,720人将死于癌症。

然而，高成本预计将阻碍整体市场成长。癌症诊断费用昂贵，对患者家庭带来沉重的经济负担。与已开发国家相比，开发中国家缺乏政府医疗保险计划。因此，没有健保的中产阶级患者群体无力负担这些检测费用。此外，许多私人保险公司也不承保开发中国家的诊断费用。因此，高成本限制了筛检工具的普及，尤其是在开发中国家。然而，随着印度和马来西亚等国医疗旅游业的快速发展，医疗和诊断方案的价格将更加亲民，预计未来几年将有所改变。

目录

第一章调查方法和范围

第二章执行摘要

第三章 癌症切片检查市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

第四章 癌症切片检查市场：按产品分類的业务分析

  • 按产品分類的市场份额，2024 年和 2033 年
  • 产品细分仪表板
  • 市场规模、预测与趋势分析（按产品划分，2021-2033 年）
  • 装置
  • 套件和耗材
  • 服务

第五章 癌症切片检查市场：按类型分類的业务分析

  • 按类型分類的市场份额，2024 年和 2033 年
  • 类型细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 组织切片检查
  • 液态生物检体
  • 其他的

第六章 癌症切片检查市场：应用业务分析

  • 应用市场份额，2024 年和 2033 年
  • 应用细分仪表板
  • 市场规模、预测与趋势分析（按应用领域划分，2021-2033 年）
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌
  • 血癌
  • 肾癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他的

第七章 癌症切片检查市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • QIAGEN
    • Illumina, Inc.
    • ANGLE plc
    • BD（Becton, Dickinson and Company）
    • Myriad Genetics, Inc.
    • Hologic, Inc.
    • Biocept, Inc.
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • F. Hoffmann-La Roche Ltd.
    • Lucence Health Inc.
    • GRAIL, Inc.
    • Guardant Health Inc.
    • Exact Sciences Corporation
    • Freenome Holdings, Inc.
    • Biodesix（Integrated Diagnostics）
    • Oncimmune
    • Epigenomics AG
    • HelioHealth（Laboratory for Advanced Medicine）
    • Genesystems, Inc.（Genesys Biolabs）
    • Chronix Biomedical, Inc.
    • Personal Genome Diagnostics Inc.
    • Natera, Inc.
    • Personalis Inc.
Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Summary

The global cancer biopsy market size was estimated at USD 32.32 billion in 2024 and is projected to reach USD 65.68 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market growth is attributed to the increasing prevalence of cancer, which is propelling the need for innovative diagnostics to provide early and effective diagnostic solutions to patients.

Moreover, the rising awareness of inherited oncology disorders and the rise in genetic testing are further anticipated to drive the growth of the cancer biopsy industry. The National Cancer Institute (NCI) 2022 update highlights that in the U.S. alone, there were approximately 20 million new cases, resulting in deaths of almost 9.7 million cancer-related deaths worldwide. These substantial figures highlight the growing cancer burden and present a significant growth opportunity for the market.

Due to the advantages of liquid biopsy technologies, massive parallel or NGS has emerged as a rapidly growing and evolving technology with increasing applications in various human Products. An increase in alterations of molecules in various types supports the usage of NGS in clinical settings, as it provides a cost- and time-effective way of detecting cancer. Tumor heterogeneity (evaluating different genes at the same time), along with the need for gene profiling, has increased the use of liquid biopsy, which is expected to propel market growth. Moreover, for various applications, such as prostate, breast, non-small-cell lung, colorectal, and ovarian cancer, liquid biopsy is used for diagnostic & screening, making it an important tool.

The increasing incidence of disease is propelling the demand for the diagnosis of cancers at early stages. For instance, as per Global Cancer Statistics 2024, reported by the American Cancer Society, approximately 20 million cancer cases were newly diagnosed in 2022, and 9.7 million people died from it globally. Moreover, the number of cancer cases is predicted to reach 35 million by 2050. When cancer is discovered early and is contained to the organ of origin before it has a chance to spread, survival rates drastically increase, and it is more likely to be effectively cured. Early detection is crucial for lowering cancer-related mortality, especially through efficient screening programs. Early detection increases patient survival rates by 5 to 10 times more than late detection. The 5-year cancer-specific survival rate is only 21% when cancer is discovered after it has spread, as opposed to 89% when it is found early & still localized.

Furthermore, the increasing number of initiatives by various organizations to raise awareness is a major reason for the growing demand for diagnostic products worldwide. Collaborations and partnerships undertaken by CDC, WHO, the National Cervical Cancer Coalition, the U.S. Preventive Services Task Force, & others are expected to drive market growth by increasing cervical cancer screening rates. In addition, major market players are undertaking initiatives to increase awareness about cervical, vulvar, and vaginal cancer, which is likely to encourage people to opt for screening at regular intervals.

For instance, in 2024, India, the U.S., Australia, and Japan launched the Quad Cancer Moonshot Initiative, which was specifically focused on eliminating cervical cancer across the Indo-Pacific region. Similarly, in October 2024, the University of New South Wales (UNSW) Sydney received a donation of USD 25.9 million from the Swire Group. This funding allowed the Kirby Institute at UNSW Sydney to screen 130,000 women in seven Pacific countries, including Fiji, Kiribati, the Republic of Marshall Islands, Samoa, Solomon Islands, Tonga, and Vanuatu, for cervical cancer.

Moreover, awareness among people about early diagnosis and available treatment options and advancements in treatments has substantially improved patient outcomes. According to a Cancer Progress Report published by the American Association for Cancer Research, it was expected that in the U.S., around 2,001,140 new cases of cancer would be diagnosed in 2024, and approximately 611,720 people might die from the Disease.

However, the high cost of diagnostic tests is anticipated to hamper the overall market growth. Diagnostic cancer tests are expensive, increasing the financial burden on families of patients. The government insurance framework is less well-defined in developing countries than in developed countries. Thus, the middle-class patient population who are uninsured cannot afford these tests. In addition, many private insurance players do not cover costs associated with diagnosis in developing countries. As a result, the high cost of diagnosis is limiting the adoption of screening tools, especially in developing countries. However, the scenario is expected to change in the coming years due to booming medical tourism in countries such as India and Malaysia, wherein healthcare treatments & diagnostic solutions are becoming affordable.

Global Cancer Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biopsy market report based on product, type, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Kits & Consumables
  • Services
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Tissue Biopsies
    • Needle Biopsies
    • Surgical Biopsies
  • Liquid Biopsies
    • Fine Needle Aspiration (FNA)
    • Core Needle Biopsy (CNB)
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancers
  • Lung Cancers
  • Prostate Cancers
  • Skin Cancers
  • Blood Cancers
  • Kidney Cancers
  • Liver Cancers
  • Pancreatic Cancers
  • Ovarian Cancers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Biopsy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Cancer Biopsy Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
  • 4.5. Kits and Consumables
    • 4.5.1. Kits and Consumables Market, 2021 - 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Biopsy Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Tissue Biopsies
    • 5.4.1. Tissue Biopsies Market, 2021 - 2033 (USD Million)
      • 5.4.1.1. Needle Biopsies
        • 5.4.1.1.1. Needle Biopsies Market, 2021 - 2033 (USD Million)
      • 5.4.1.2. Surgical Biopsies
        • 5.4.1.2.1. Surgical Biopsies Market, 2021 - 2033 (USD Million)
  • 5.5. Liquid Biopsies
    • 5.5.1. Liquid Biopsies Market, 2021 - 2033 (USD Million)
      • 5.5.1.1. Fine Needle Aspiration (FNA)
        • 5.5.1.1.1. Fine Needle Aspiration (FNA) Market, 2021 - 2033 (USD Million)
      • 5.5.1.2. Core Needle Biopsy (CNB)
        • 5.5.1.2.1. Core Needle Biopsy (CNB) Market, 2021 - 2033 (USD Million)
  • 5.6. Others

Chapter 6. Cancer Biopsy Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 6.4. Breast Cancer
    • 6.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Colorectal Cancer
    • 6.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Cervical Cancers
    • 6.6.1. Cervical Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Lung Cancers
    • 6.7.1. Lung Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Prostate Cancers
    • 6.8.1. Prostate Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Skin Cancers
    • 6.9.1. Skin Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Blood Cancers
    • 6.10.1. Blood Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Kidney Cancers
    • 6.11.1. Kidney Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Liver Cancers
    • 6.12.1. Liver Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Pancreatic Cancers
    • 6.13.1. Pancreatic Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.14. Ovarian Cancers
    • 6.14.1. Ovarian Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.15. Others
    • 6.15.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Cancer Biopsy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. U.S. Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Canada Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Mexico Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. UK Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Germany Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. France Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Italy Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Spain Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Denmark Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Sweden Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Norway Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. India Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Australia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. South Korea Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Thailand Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. South Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Saudi Arabia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. UAE Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Kuwait Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. QIAGEN
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Illumina, Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. ANGLE plc
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BD (Becton, Dickinson and Company)
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Myriad Genetics, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Hologic, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Biocept, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Thermo Fisher Scientific, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Danaher
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. F. Hoffmann-La Roche Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Lucence Health Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. GRAIL, Inc.
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Guardant Health Inc.
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Exact Sciences Corporation
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives
    • 8.5.15. Freenome Holdings, Inc.
      • 8.5.15.1. Overview
      • 8.5.15.2. Financial Performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic Initiatives
    • 8.5.16. Biodesix (Integrated Diagnostics)
      • 8.5.16.1. Overview
      • 8.5.16.2. Financial Performance
      • 8.5.16.3. Product Benchmarking
      • 8.5.16.4. Strategic Initiatives
    • 8.5.17. Oncimmune
      • 8.5.17.1. Overview
      • 8.5.17.2. Financial Performance
      • 8.5.17.3. Product Benchmarking
      • 8.5.17.4. Strategic Initiatives
    • 8.5.18. Epigenomics AG
      • 8.5.18.1. Overview
      • 8.5.18.2. Financial Performance
      • 8.5.18.3. Product Benchmarking
      • 8.5.18.4. Strategic Initiatives
    • 8.5.19. HelioHealth (Laboratory for Advanced Medicine)
      • 8.5.19.1. Overview
      • 8.5.19.2. Financial Performance
      • 8.5.19.3. Product Benchmarking
      • 8.5.19.4. Strategic Initiatives
    • 8.5.20. Genesystems, Inc. (Genesys Biolabs)
      • 8.5.20.1. Overview
      • 8.5.20.2. Financial Performance
      • 8.5.20.3. Product Benchmarking
      • 8.5.20.4. Strategic Initiatives
    • 8.5.21. Chronix Biomedical, Inc.
      • 8.5.21.1. Overview
      • 8.5.21.2. Financial Performance
      • 8.5.21.3. Product Benchmarking
      • 8.5.21.4. Strategic Initiatives
    • 8.5.22. Personal Genome Diagnostics Inc.
      • 8.5.22.1. Overview
      • 8.5.22.2. Financial Performance
      • 8.5.22.3. Product Benchmarking
      • 8.5.22.4. Strategic Initiatives
    • 8.5.23. Natera, Inc.
      • 8.5.23.1. Overview
      • 8.5.23.2. Financial Performance
      • 8.5.23.3. Product Benchmarking
      • 8.5.23.4. Strategic Initiatives
    • 8.5.24. Personalis Inc.
      • 8.5.24.1. Overview
      • 8.5.24.2. Financial Performance
      • 8.5.24.3. Product Benchmarking
      • 8.5.24.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Cancer Biopsy Market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 5. Global Cancer Biopsy Market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Cancer Biopsy Market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 8. North America Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 9. North America Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 10. U.S. Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 11. U.S. Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 12. U.S. Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 13. Canada Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 14. Canada Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 15. Canada Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 16. Mexico Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 17. Mexico Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 18. Mexico Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 19. Europe Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 20. Europe Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 21. Europe Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Europe Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 23. UK Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 24. UK Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 25. UK Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 26. Germany Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 27. Germany Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 28. Germany Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 29. France Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 30. France Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 31. France Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 32. Italy Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 33. Italy Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 34. Italy Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 35. Spain Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 36. Spain Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 37. Spain Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 38. Norway Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 39. Norway Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 40. Norway Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 41. Denmark Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 42. Denmark Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Denmark Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 44. Sweden Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 45. Sweden Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 46. Sweden Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 47. Asia Pacific Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 51. Japan Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 52. Japan Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 53. Japan Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 54. China Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 55. China Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 56. China Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 57. India Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 58. India Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 59. India Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 60. Australia Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 61. Australia Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 62. Australia Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 63. South Korea Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 64. South Korea Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 65. South Korea Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 66. Thailand Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 67. Thailand Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. Thailand Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 69. Latin America Cancer Biopsy Market, by country, 2021 - 2033 (USD Million)
  • Table 70. Latin America Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 71. Latin America Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 72. Latin America Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 73. Brazil Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 74. Brazil Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 75. Brazil Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 76. Argentina Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 77. Argentina Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 78. Argentina Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 79. Middle East & Africa Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 83. South Africa Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 84. South Africa Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 85. South Africa Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 86. Saudi Arabia Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 89. UAE Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 90. UAE Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 91. UAE Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 92. Kuwait Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 93. Kuwait Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 94. Kuwait Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer Biopsy Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and Product outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Cancer Biopsy Market dynamics
  • Fig. 12 Cancer Biopsy Market: Porter's five forces analysis
  • Fig. 13 Cancer Biopsy Market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Instruments market, 2021 - 2033 (USD Million)
  • Fig. 16 Kits and Consumables market, 2021 - 2033 (USD Million)
  • Fig. 17 Services market, 2021 - 2033 (USD Million)
  • Fig. 18 Type market, 2021 - 2033 (USD Million)
  • Fig. 19 Tissue Biopsies market, 2021 - 2033 (USD Million)
  • Fig. 20 Liquid Biopsies market, 2021 - 2033 (USD Million)
  • Fig. 21 Others market, 2021 - 2033 (USD Million)
  • Fig. 22 Application market, 2021 - 2033 (USD Million)
  • Fig. 23 Breast Cancer market, 2021 - 2033 (USD Million)
  • Fig. 24 Colorectal Cancer market, 2021 - 2033 (USD Million)
  • Fig. 25 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 26 Lung Cancer market, 2021 - 2033 (USD Million)
  • Fig. 27 Prostate Cancer market, 2021 - 2033 (USD Million)
  • Fig. 28 Skin Cancer market, 2021 - 2033 (USD Million)
  • Fig. 29 Blood Cancer market, 2021 - 2033 (USD Million)
  • Fig. 30 Kidney Cancer market, 2021 - 2033 (USD Million)
  • Fig. 31 Liver Cancer market, 2021 - 2033 (USD Million)
  • Fig. 32 Pancreatic Cancer market, 2021 - 2033 (USD Million)
  • Fig. 33 Ovarian Cancer market, 2021 - 2033 (USD Million)
  • Fig. 34 Others market, 2021 - 2033 (USD Million)
  • Fig. 35 Cancer Biopsy Market revenue, by region
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. country dynamics
  • Fig. 39 U.S. Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 40 Canada country dynamics
  • Fig. 41 Canada Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 42 Mexico country dynamics
  • Fig. 43 Mexico Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 44 Europe Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 45 UK country dynamics
  • Fig. 46 UK Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 47 Germany country dynamics
  • Fig. 48 Germany Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 49 France country dynamics
  • Fig. 50 France Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 51 Italy country dynamics
  • Fig. 52 Italy Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 53 Spain country dynamics
  • Fig. 54 Spain Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 55 Norway country dynamics
  • Fig. 56 Norway Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 57 Sweden country dynamics
  • Fig. 58 Sweden Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 59 Denmark country dynamics
  • Fig. 60 Denmark Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 62 Japan country dynamics
  • Fig. 63 Japan Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 66 India country dynamics
  • Fig. 67 India Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 68 Australia country dynamics
  • Fig. 69 Australia Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 70 South Korea country dynamics
  • Fig. 71 South Korea Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 72 Thailand country dynamics
  • Fig. 73 Thailand Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 75 Brazil country dynamics
  • Fig. 76 Brazil Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 77 Argentina country dynamics
  • Fig. 78 Argentina Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 79 MEA Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 80 South Africa country dynamics
  • Fig. 81 South Africa Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 82 Saudi Arabia country dynamics
  • Fig. 83 Saudi Arabia Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 84 UAE country dynamics
  • Fig. 85 UAE Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 88 Company categorization
  • Fig. 89 Company market position analysis
  • Fig. 90 Strategic framework